How You Can Be Involved in the First FDA Ad Comm Meeting for a Gene Therapy Product for Duchenne
Last week, Sarepta announced that the FDA Center for Biologics Evaluation and Research (CBER), Office of Therapeutic Products had informed the company that an advisory committee meeting will be scheduled prior to the PDUFA (or…Learn More